Renal Mass

Earn CME/CE in your profession:


Continuing Education Activity

Renal mass is an abnormal growth in the kidney. The majority of renal masses are benign; however, a significant number of them require further intervention. This activity describes the background, evaluation, and intervention of renal mass and highlights an interprofessional team's role in improving care in patients with this condition.

Objectives:

  • Review the etiology of renal mass, specifically renal cell carcinoma.
  • Summarize the evaluation of renal masses.
  • Describe the management of patients with renal mass.
  • Outline some interprofessional team strategies that can improve patient outcomes in renal mass cases.

Introduction

Renal mass is an abnormal growth in the kidney. The majority of renal masses are benign; however, a significant number of them require further intervention. The retroperitoneum's anatomy, signs, symptoms, or physical examination are insufficient for detecting renal masses. Imaging modalities such as CT, MRI, or ultrasound are used to diagnose such masses. 

Renal masses are classified into either solid or cystic. This review will focus on the solid tumor with minimal discussion on the cystic type. One of the main concerns for a solid renal mass is carcinoma. There were about 74,000 new cases in 2019; of these, it is expected that 15,000 patients will die from cancer.

The five-year survival rate increases with early diagnosis. The survival rate for stage 1 and 2 renal cell carcinoma (RCC) is above 90% versus below 15% for certain types of stage 3 or metastatic disease.[1] Therefore, it is essential to diagnose and evaluate new renal masses in a timely manner to improve our patients' quality of life and prognosis. Arguably, the most critical indication of malignancy is the size of a tumor. Renal mass is commonly divided into two size categories; less than 4cm and more than 4cm. Because of the advancement of imaging tests such as CT, MRI, and ultrasound, more masses are detected incidentally during other workups. A cross-sectional study performed in 2011 showed that renal masses are found incidentally in 14% of patients who underwent CT colonography.[2]

Since renal mass is a diverse subject with many nuances in both treatment and management, this review will explore renal mass, emphasizing small renal masses because of clinical practice relevance. We will examine the etiologies, diagnosis, and management of renal mass.

Etiology

The causes of renal mass are multifactorial. Specifically, studies have found that smoking increases RCC's risk in a dose-dependent fashion with renal cell carcinoma. Other classical precipitation agents such as benzene, herbicides, and vinyl are commonly known to increase carcinoma risk.

Furthermore, medications have also been implicated; A prospective study by Cho et al. showed that NSAIDs correlates with the increased risk of cancer.[3] However, this is the first kind of such study, and further evaluation and validation are needed.

Genetics plays a role in the formation of renal masses as well. The most common example is polycystic kidney disease. In this condition, there are autosomal dominant and autosomal recessive forms. The recessive form is more aggressive and often fatal. Both of these have a high potential for aggressive malignant kidney masses. Other examples of disorders associated with the development of renal masses include Von Hippel-Lindau and Birth-Hogg Dube syndromes.

Interestingly, medical pathologies such as hepatitis C and kidney stones are also associated with RCC.[4][5]

Epidemiology

Kidney and renal pelvic cancers are the 12th most common cancer in the US, with more males affected than females. Middle age Caucasian and African Americans are equally affected, with Asians being the least affected. US Census found that there are around ~7400 cases in 2019. There are approximately 15,000 deaths yearly, with RCC accounts for approximately 80% of those deaths.

Overall, renal masses have increased in the past decades because of improved sensitivity and usage frequency of advanced imaging modalities such as MRIs and CTs. Therefore, it is not surprising to find such renal mass in healthy individuals. On the other hand, new malignant kidney mass cases have been holding steady from 2008 to 2016, with the five-year survival rate steadily improving due to advancement in detection and intervention.

History and Physical

Renal masses are frequently found incidentally without signs or symptoms. The triad of hematuria, flank pain, and flank mass is seen infrequently in modern medicine because they, more likely than not, have already been detected by imaging before symptomatology. The classic triad is observed in approximately 15% of cases, and most of those are in advanced stages. However, if these findings are present, then it warrants further evaluation. New hypertension, unintentional weight loss, and night sweat are nonspecific but essential in elucidating the differential diagnosis. Laboratory findings for anemia or polycythemia, hypercalcemia are useful in this case. Physical examination should evaluate for varicoceles in the setting of tumor invasion.

History taking should be thorough and exploring information such as smoking history, eating habits, exercise status, comorbidities, and exposures to known cancer-causing agents. Literature suggests that obesity, hypertension, and smoking are present in up to 50% of cases.[6] Furthermore, high BMI, triglyceride, and blood glucose seem to increase RCC risks.[7] Occupation exposures to dye-containing hydrocarbons have long been thought to cause RCC, but recent literature is still inconclusive, requiring further assessment.

Family history and comorbidities are significant if positive. Research has linked conditions such as ESRD to RCC because of the tendency to induce the kidney's cystic formation, leading to aberrant cell formation. Also, patients with a family history of genetic conditions such as polycystic kidney disease are at a higher risk, requiring close monitoring.

Evaluation

Evaluation of renal mass is diverse, depending on the patient's presentation, demographic, and symptomatology. Patients with symptoms and signs such as hematuria, palpable flank mass, or flank pain should be further evaluated. Patients should undergo laboratory tests and advanced imaging such as CT, MRI, and ultrasound. The decision to use CT or MRI depends on the tumor and the patient's clinical characteristics. It is better to use CT when fast imaging acquisition is preferred, or there is a contraindication to MRI, such as with patients with metallic implants. In contrast, MRI is preferred for smaller renal lesions' characterization with the benefits of no radiation exposure.

It is essential to evaluate asymptomatic patients with incidental findings of renal mass. Most renal masses are benign, but there is a significant concern for carcinoma. Some signs are notable on advanced imaging to differentiate benign from malignancy. For instance, on a CT scan, fat is less dense than water and soft tissues. Therefore, Hounsfield units of less than -10 to - 20 have more fat content and likely indicate an angiolipoma, a benign tumor.[8] In contrast, a strong enhancement characteristic indicates that the tumor is lipid poor with a much higher malignancy potential.

If there is a suspicion for renal cell carcinoma, metastasis needs to be evaluated. The most common sites for metastatic RCC are the lung (75%), followed by soft tissues, bone, liver, and brain. It is helpful to evaluate such patients with advanced imaging such as CT chest, CT brain, and bones scan. Laboratory workup includes UA, CBC, LFTs, calcium, CMP are helpful in the examination. A para-neoplastic syndrome is frequently found in RCC; therefore, hyperkalemia and elevated ESR are useful markers in this setting. 

Also, tumor size is an essential consideration in the evaluation. In general, less than 3-4cm tumor size has lower malignant potential than larger tumors. Up to 40% of 2cm renal masses are benign and only a small percentage, 10%, are high-grade RCC.[9][10] In contrast, up to 30% of 4cm or larger renal masses are high-grade cancer.[11] There is a lower threshold for further evaluation with larger renal masses due to higher malignancy potential.

Treatment / Management

Renal mass management varies depending on multiple factors, including patient and size, shape, and renal tumor pathology. Different interventions include close monitoring, biopsy, surgical resection, and thermal ablation. The decision to choose one over another depends on balancing the risks and benefits. As with many other interventions, it is essential to take the age, comorbidities, risk factors, and ESRD status of a patient into consideration. For example, it is beneficial to offer patients a short life expectancy of either surveillance or ablation, depending on tumor characteristics. They are more likely to succumb to their comorbidities or surgery than from the complications of the tumor.

A renal biopsy is indicated when the renal mass characteristic is unrevealing. Significant non-diagnostic results (15%) after a renal biopsy require patients to undergo additional biopsies.[12] There are also risks of hematoma, renal failure, and other complications. Due to its limitation, a biopsy is only indicated in certain situations. Biopsies are commonly performed when a patient is a surgical candidate, and the biopsy results help guide management. Biopsies are also of value to provide tumor pathology. Biopsies are not indicated if the result would not impact management. One typical example when a biopsy would not be justified is when the mass is less than 1 cm. Please see Renal Biopsy by Michael Young; Stephen W. Leslie published via StatPearls for further discussion. 

Thermal ablation is indicated in patients who are not surgical candidates. It is most useful for tumor size less than 3cm. Ablations are less invasive than surgery; however, it increases the risk of recurrence of cancer, the need for close and active surveillance, and the potential for further treatment. Percutaneous Biopsy is recommended for post-procedural surveillance.

Surgery is the most definitive intervention for malignant renal masses. The two most common approaches are partial and radical nephrectomy. Partial nephrectomy is preferred as it preserves kidney function compared to radical nephrectomy, especially in patients with CKD stage 3 or worse.[13] However, there is an increase in the risk of bleeding in partial nephrectomy. Total nephrectomy should be considered when a tumor has unfavorable pathology or is larger than 5cm.[14]

Active surveillance is indicated in many situations, especially in small masses with benign characteristics. When a tumor is less than 1cm with a gradual growth rate, further imaging and biopsy are not beneficial due to minimal malignant transformation risks. These patients should be offered active surveillance instead. Surveillance should also be offered to patients who are not surgical candidates. An elderly patient with a short life expectancy with a less than 4 cm tumor size is a suitable candidate for active surveillance. Although there is no unified guideline for the frequency of active surveillance, consensus indicates that renal ultrasound, CT, or MRI can be used for monitoring renal mass every 3 to 6 months for the first year. It can be spaced out depending on the renal pathology and progression.[15]

Differential Diagnosis

Whenever there is a renal mass, it is always important to rule out infection and abscess, as antibiotics are required for such treatment. When an infection is ruled out, further investigation is needed for malignant etiologies such as renal cell carcinoma, metastasis, or lymphoma. While investigating for malignancy, it is crucial to identify benign tumors such as oncocytoma, angiomyolipoma, or adenoma. These usually require active surveillance, with no interventions needed.

Prognosis

The prognosis for renal mass depends on the tumor identified. RCC accounts for about 15,000 deaths or 80% of kidney and renal pelvic cancers. As with most other cancer, the survival rate improves with early diagnosis and treatment. According to the American Cancer Society, the localized disease in stages 1 and 2 has an above 90% survival rate, while distant metastasis, such as in stage 4, has a 13% 5-years survival rate. In stage 3, the survival rate for patients who underwent nephrectomy is up to 70%. However, invasion into the renal vein indicates a poorer prognosis.[16]

For other types of tumors, classical variant angiomyolipomas have a prolonged growth rate. In one case report, 90% of tumors with a size of less than 1.5cm have no growth over the five-year follow-up.[17] The epithelioid variants, however, have a small but significant potential for malignant transformation. A small case series indicates that out of 40 participants, about 9 (26%) have malignant transformation.[18]

Oncocytoma is mostly benign and well organized compared to RCC. They are encapsulated and not invasive. However, RCC can be seen in up to 30% of patients who have oncocytoma. As a result, they should be closely monitored for renal malignancy.

A metanephric adenoma is mostly benign; however, they can present similarly to RCC in symptomatology. Patients can present with the classical triad of flank pain, hematuria, and a palpable mass. The critical difference is that they present more frequently in females than males, unlike their RCC counterparts. Histology is the primary way to diagnose this type of mass. Up to 90% of the adenoma have a BRAF V600 mutation.[19] Due to the tumor pathology, there is no surgical indication since it is benign.

Complications

It is vital to balance the risks and benefits of intervention versus surveillance. When surgery is indicated, it is essential to evaluate the risk of infection, bleeding, and renal failure. Therefore, it is essential to assess patients before undergoing invasive procedures. When a patient is not a candidate for surgery, ablation is an option. Although there are fewer complications than surgery, the risk for recurrent, requiring multiple treatment sessions, is higher in the ablation group. Providers must inform patients about the risks and benefits before undergoing interventions.

Consultations

Specialists such as oncologists and urologists should be consulted for the evaluation and management of certain renal masses.

Deterrence and Patient Education

It is essential to educate patients on the risk factors for renal cell carcinoma, such as smoking, alcohol use, obesity, genetic, environmental exposure, and dialysis. Patients should be counseled to quit smoking and alcohol and increase their dietary intake of vegetables and fruits. These qualities have been shown to correlate with a lower rate of renal cancer.

Depending on the clinical and renal pathology, patients should be offered genetic counseling to the patient and their families, such as Von-Hippel Lindal, hereditary leiomyomatosis and renal cell cancer, Birt-Hogg-Dubé syndrome, and hereditary papillary renal carcinoma.

Workers who have been exposed to toxic agents such as polycyclic aromatic hydrocarbon groups should be further evaluated. Still, studies have been inconclusive about the actual link of such exposure to RCC.[20]

Literature has linked medications to renal cell carcinoma. A 2011 prospective study showed that the more prolonged use of non-aspirin NSAID correlates with increased RCC risk.[3] This is the first study of its kind, and further evaluation is needed to solidify this finding. It is essential to discuss the risks and benefits of their medications with patients.

Enhancing Healthcare Team Outcomes

Interprofessional team involvement is essential in preventing and treating renal mass. With the guidance of dietitians and physical therapists, patients can appreciate diet and weight loss for their overall health and reduce malignant renal mass risk.

Primary care providers and nurses need to reinforce the importance of follow-up, medication compliance, and cessation of alcohol and cigarettes. Furthermore, urologists and oncologists, along with primary care providers and pharmacists, can optimize treatment guidance and interventions while reducing complications. By collaboration and communication, an interprofessional team will offer improved delivery care for patients with renal masses.


Article Details

Article Author

Brian Ballard

Article Editor:

Nilmarie Guzman

Updated:

3/5/2021 1:49:37 AM

PubMed Link:

Renal Mass

References

[1]

Motzer RJ,Bander NH,Nanus DM, Renal-cell carcinoma. The New England journal of medicine. 1996 Sep 19;     [PubMed PMID: 8778606]

[2]

O'Connor SD,Pickhardt PJ,Kim DH,Oliva MR,Silverman SG, Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management. AJR. American journal of roentgenology. 2011 Jul;     [PubMed PMID: 21701022]

[3]

Cho E,Curhan G,Hankinson SE,Kantoff P,Atkins MB,Stampfer M,Choueiri TK, Prospective evaluation of analgesic use and risk of renal cell cancer. Archives of internal medicine. 2011 Sep 12;     [PubMed PMID: 21911634]

[4]

Gonzalez HC,Lamerato L,Rogers CG,Gordon SC, Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Digestive diseases and sciences. 2015 Jun;     [PubMed PMID: 25592719]

[5]

Cheungpasitporn W,Thongprayoon C,O'Corragain OA,Edmonds PJ,Ungprasert P,Kittanamongkolchai W,Erickson SB, The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis. QJM : monthly journal of the Association of Physicians. 2015 Mar;     [PubMed PMID: 25208892]

[6]

Chow WH,Dong LM,Devesa SS, Epidemiology and risk factors for kidney cancer. Nature reviews. Urology. 2010 May;     [PubMed PMID: 20448658]

[7]

Häggström C,Rapp K,Stocks T,Manjer J,Bjørge T,Ulmer H,Engeland A,Almqvist M,Concin H,Selmer R,Ljungberg B,Tretli S,Nagel G,Hallmans G,Jonsson H,Stattin P, Metabolic factors associated with risk of renal cell carcinoma. PloS one. 2013;     [PubMed PMID: 23468995]

[8]

Davenport MS,Neville AM,Ellis JH,Cohan RH,Chaudhry HS,Leder RA, Diagnosis of renal angiomyolipoma with hounsfield unit thresholds: effect of size of region of interest and nephrographic phase imaging. Radiology. 2011 Jul;     [PubMed PMID: 21555349]

[9]

Frank I,Blute ML,Cheville JC,Lohse CM,Weaver AL,Zincke H, Solid renal tumors: an analysis of pathological features related to tumor size. The Journal of urology. 2003 Dec;     [PubMed PMID: 14634382]

[10]

Johnson DC,Vukina J,Smith AB,Meyer AM,Wheeler SB,Kuo TM,Tan HJ,Woods ME,Raynor MC,Wallen EM,Pruthi RS,Nielsen ME, Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. The Journal of urology. 2015 Jan;     [PubMed PMID: 25072182]

[11]

Thompson RH,Kurta JM,Kaag M,Tickoo SK,Kundu S,Katz D,Nogueira L,Reuter VE,Russo P, Tumor size is associated with malignant potential in renal cell carcinoma cases. The Journal of urology. 2009 May;     [PubMed PMID: 19286217]

[12]

Sutherland EL,Choromanska A,Al-Katib S,Coffey M, Outcomes of ultrasound guided renal mass biopsies. Journal of ultrasound. 2018 Jun;     [PubMed PMID: 29696566]

[13]

Campbell S,Uzzo RG,Allaf ME,Bass EB,Cadeddu JA,Chang A,Clark PE,Davis BJ,Derweesh IH,Giambarresi L,Gervais DA,Hu SL,Lane BR,Leibovich BC,Pierorazio PM, Renal Mass and Localized Renal Cancer: AUA Guideline. The Journal of urology. 2017 Sep;     [PubMed PMID: 28479239]

[14]

Van Poppel H,Da Pozzo L,Albrecht W,Matveev V,Bono A,Borkowski A,Colombel M,Klotz L,Skinner E,Keane T,Marreaud S,Collette S,Sylvester R, A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European urology. 2011 Apr;     [PubMed PMID: 21186077]

[15]

Gordetsky J,Eich ML,Garapati M,Del Carmen Rodriguez Pena M,Rais-Bahrami S, Active Surveillance of Small Renal Masses. Urology. 2019 Jan;     [PubMed PMID: 30267727]

[16]

Anderson CB,Clark PE,Morgan TM,Stratton KL,Herrell SD,Davis R,Cookson MS,Smith JA Jr,Chang SS, Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul;     [PubMed PMID: 21550647]

[17]

Yip SK,Cheng WS, Management of renal angiomyolipoma: a report of 53 cases. BJU international. 1999 Dec;     [PubMed PMID: 10651524]

[18]

Brimo F,Robinson B,Guo C,Zhou M,Latour M,Epstein JI, Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. The American journal of surgical pathology. 2010 May;     [PubMed PMID: 20410812]

[19]

Choueiri TK,Cheville J,Palescandolo E,Fay AP,Kantoff PW,Atkins MB,McKenney JK,Brown V,Lampron ME,Zhou M,Hirsch MS,Signoretti S, BRAF mutations in metanephric adenoma of the kidney. European urology. 2012 Nov;     [PubMed PMID: 22727996]

[20]

Capitanio U,Bensalah K,Bex A,Boorjian SA,Bray F,Coleman J,Gore JL,Sun M,Wood C,Russo P, Epidemiology of Renal Cell Carcinoma. European urology. 2019 Jan;     [PubMed PMID: 30243799]